Articles

Innovative Development: High-Purity THC Distillate for PharmaceuticalUse

In collaboration with our esteemed partners, Siegfried AG and Velmed AG, we are advancing the development of a high-purity THC distillate for pharmaceutical applications. As part of a Swissmedic-approved pilot project, we are setting new standards in the processing and purity of medical cannabis.

This groundbreaking project consists of two key phases:

Phase A: Feasibility Study & Implementation of Analytical Methods

The first milestone involves a detailed laboratory study aimed at validating the efficiency and safety of the extraction process:

Optimization of the extraction process to obtain a high-quality THC crude extract

Adjustment to Siegfried standards through fine-tuning processes and conducting a comprehensive safety risk assessment for the storage and handling of THC

Stability testing of all relevant processing steps to define optimal storage conditions

At the same time, we implement all necessary analytical methods for new raw materials, intermediates, and the final active pharmaceutical ingredient (API).

Phase B: Laboratory Production & Validation of Analytical Methods

After successful feasibility testing, we proceed with the laboratory production of high-purity THC samples and the validation of analytical methods. This phase includes:

Validation of analytical methods for product release (including HPLC for assay/impurities, GC-HS for residual solvents, ICP-MS for elemental impurities, and microbiological testing)

Adjustment of standardized Siegfried methods for verifying specific residues and substances

Production of laboratory samples of up to 250g per batch, ensuring the scalability of the manufacturing process

Why This Project is Shaping the Future of Pharmaceutical Cannabis Production

With this pilot project, we are setting new industry benchmarks for pharmaceutical-grade THC processing. Our close collaboration with Siegfried AG and Velmed AG ensures that our THC distillate meets the highest standards of safety, purity, and quality.

🔬 Highest Pharmaceutical Quality: Our processes are Swissmedic-compliant and optimized to the strictest GMP standards

🚀 Innovative Extraction & Analytical Methods: Maximum efficiency and purity in every phase of production

Safety & Transparency: Comprehensive quality controls ensure a stable and reliable supply chain

By developing a high-quality THC distillate for pharmaceutical use, we are taking a significant step toward the future of the medical cannabis industry.

Want to learn more about our pharmaceutical innovations? Contact us – we are committed to quality, safety, and progress in cannabis research!

Articles

Innovative Development: High-Purity THC Distillate for PharmaceuticalUse

In collaboration with our esteemed partners, Siegfried AG and Velmed AG, we are advancing the development of...

Quality and Safety at the Highest Level – The Licenses of UNIXIS AG

Since our founding in 2022, UNIXIS AG has been committed to the highest quality standards and continuous...

UNIXIS AG: Pioneer in the Import of Medical Cannabis

UNIXIS AG is setting new standards in the Swiss medical cannabis market. With our narcotics license and...